Navigation Links
Thermal Angel Supports Infection Control During the Golden Hour
Date:4/27/2009

DALLAS, April 27 /PRNewswire/ -- Estill Medical Technologies, Inc., the industry leader in portable blood and IV fluid warming therapy, announces the expansion of its Thermal Angel sales and marketing efforts. The Thermal Angel reduces the chance of mortality by quickly controlling core body temperature and infection risk.

The Thermal Angel is crucial to critical care administration. In emergency medicine, the golden hour refers to the first 60 minutes after the occurrence of a multi-system trauma. It is widely believed that the victim's survival chances are greatest if they receive definitive care within this first hour of injury.

So, how does the Thermal Angel work? It is portable, battery-powered, and disposable. It warms IV fluid and blood and is capable of initiating intravenous application within 45 seconds. It also prevents fluid-induced hypothermia, which can create numerous life-threatening conditions.

"Due to its portable and adaptive nature," Jay Lopez, president of Estill Medical Technologies, Inc. says, "we've had 93 countries request the Thermal Angel, but our primary focus has been to provide supplies for our military troops."

A platoon medic with the U.S. Army Ranger Regiment explains that, "The Thermal Angel Blood and IV Infusion Warmer is an excellent piece of medical equipment; it's essential to our deployment packing list. It's compact, lightweight, and easy to use."

A military medic must be economical in his choice of equipment and the Thermal Angel is cost efficient and requires minimal time for charging and operation. And, because the Thermal Angel is disposable, infection control becomes much more manageable. It also provides peace of mind should unexpected situations such as delays occur.

"As a result of the success our military has had using the Thermal Angel in medical field kits, on Black Hawk helicopters, and in ground vehi
'/>"/>

SOURCE Estill Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ANSYS and Network Analysis Team Up to Improve Thermal Simulation
2. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
3. How to enhance non-thermal effects of ultrasound
4. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
5. Alzheimers Foundation of America to Display Quilt to Remember in Los Angeles
6. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
7. Fifth Annual Avon Walk for Breast Cancer Los Angeles Raises $4.3 Million
8. British Council and Los Angeles Area Universities Partner to Host Transatlantic Dialogues
9. Los Angeles Area Chamber of Commerce Endorses Governor Schwarzeneggers Health Care Proposal
10. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
11. Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... According to a recent Washington Post study, approximately 20% ... psychologically damaged. Among them are a substantial number with ... suicide among PTSD sufferers has become unacceptable to Army ... research from Tel Aviv University, however, doctors will now ...
... , , , ... NEW YORK, Sept. 2 Today, Tim Gunn, television host and ... officer of Liz Claiborne, Inc., is hosting the Ad dressing Psoriasis(TM) ... fashion show recognizes people with moderate to severe plaque psoriasis who have ...
... fibrillation patients drink lots of coffee, don,t eat right, ... People who drink lots of coffee but who don,t ... atrial fibrillation, a new study shows. , Italian researchers ... heart arrhythmia to supply information about their dietary habits, ...
... , , , ... FTER), which, through its ABTTC Inc. division, provides drug and ... with the highest levels of accreditation, announced today that its ... Gaskin on the Company,s recent successes, management team and shareholder ...
... Fla., Sept. 2 Cinergy Health, a nationwide provider of Limited ... chief medical director. As Cinergy Health,s chief medical director, Dr. Lewin ... studies and emerging research to the doctor patient relationship and health ... have Dr. Lewin join the Cinergy Health team," said Daniel Touizer, ...
... , INDIANAPOLIS, Sept. 2 Eli Lilly and Company ... given the Epsilon "Star of Highest Magnitude" Award and has been ... Data Processing Associates (BDPA) and WorkplaceDiversity.com. The Epsilon Award is ... a workplace and environment that supports the advancement of African-Americans in ...
Cached Medicine News:Health News:Keeping the suicidal soldier alive 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 3Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 4Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 5Health News:Caffeine Without Healthy Diet Linked to Heart Risk 2Health News:Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed 2Health News:Cinergy Health Names Dr. Margaret Lewin Chief Medical Director 2Health News:Lilly Named Best Company for Blacks in Technology 2
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Third Quarter 2007, HAYWARD, Calif., June 04, ... from a dose-escalating,Phase 1b clinical trial of ... with bortezomib (Velcade(R)), showing a,high degree of ... myeloma who had previously progressed following treatment,with ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, ... Corp. and its,co-development partner Astellas Pharma US, ... completed Phase 3 clinical,study, called ACT 2. ... of,the intravenous formulation of vernakalant hydrochloride,("vernakalant (iv)") ...
Cached Medicine Technology:Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 2Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 3Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 4Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 5Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 6Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: